peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GnRH agonist · nonapeptide analog

Leuprolide

/LOO-pro-lide/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

Lupron Depot

Intramuscular depot

Product-line indications include prostate cancer and selected gynecologic uses.

Find official label ↗
02

Eligard

Subcutaneous depot

Advanced prostate cancer.

Find official label ↗
03

Fensolvi

Subcutaneous depot

Central precocious puberty.

Find official label ↗
04

Camcevi

Subcutaneous depot

Advanced prostate cancer.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Continuous GnRH receptor stimulation initially raises and then suppresses LH and FSH, reducing gonadal steroid production.Mechanism source
Labeled-use boundary
The initial hormone flare, depot interval, and indication must be interpreted from the exact product label.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Who should avoid it

  • Pregnancy for products where fetal harm applies
  • Serious hypersensitivity to GnRH analogs or excipients
  • Product-specific restrictions
Contraindications

More common effects

  • Hot flashes
  • Injection-site reactions
  • Sweating
  • Fatigue
  • Sexual dysfunction
  • Headache
Adverse reactions

Important serious risks

  • Tumor flare and transient symptom worsening
  • Metabolic and cardiovascular effects
  • Bone mineral density loss
  • QT prolongation
  • Convulsions
  • Psychiatric effects
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

A biphasic endocrine effect

Initial gonadotropin stimulation precedes suppression with continuous exposure.

Supporting source
Evidence form
Established endocrine pharmacology
Keep in view
Early flare can be clinically consequential.
02

Depot engineering defines use

One-, three-, four-, and six-month products are distinct dosage forms.

Supporting source
Evidence form
Product-specific clinical programs
Keep in view
A shared ingredient does not make depots interchangeable.
03

Evidence crosses specialties

The ingredient appears in oncology, gynecology, and pediatric endocrine products.

Supporting source
Evidence form
Multiple approved indications
Keep in view
Each specialty requires its own outcome and safety context.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Lupron Depot prescribing information

    Current DailyMed prostate-cancer depot label with product-specific intervals and warnings.

    Open source ↗
  2. 02Literature index
    Every PubMed result for leuprolide

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for leuprolide

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    leuprolide chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗